RANCHO SANTA MARGARITA, Calif., July 24, 2002 (PRIMEZONE) - BioCurex (OTCBB:BOCX) announces another important distribution deal for its novel cancer diagnostic kits. P2000 Comercializacao de Produtos Farmaceuticos SA ("P2000"), a leading distributor of biotech and pharmaceutical products based in Lisbon, will market BioCurex's current product offerings, including proprietary Histo-RECAF(TM) and Cryo- RECAF(TM) kits, as its exclusive distributor in Portugal.
P2000 will purchase a specified number of kits from BioCurex for resale into Portugal each quarter of a multi-year agreement. BioCurex's products will be sold by a direct sales force of 15 representatives focusing on the pathology laboratory and hospital market sectors. Initial sales will begin after documentation supporting importation of the product into Portugal has been submitted to local government authorities. This is expected to take 2-3 months.
Dr. Paul D Slowey, BioCurex's CEO commented: "This is an exciting agreement for BioCurex. It not only represents our first penetration into the European market, a strong potential growth area for our products, but it also demonstrates our intent to expand our distribution capabilities in the EU. P2000 is a dynamic, rapidly expanding company who focuses on "niche market" products and has a habit of establishing market-leadership with products they represent in Portugal. The International market is a major focus area for BioCurex products and we will continue to add functional distributors to ensure rapid introduction of our diagnostic portfolio."
P2000's President Paulo Castro added: "We are delighted to be working with BioCurex and their novel cancer detection products. This deal represents a breakthrough for both companies and will offer significant benefits for both physicians and patients in Portugal."
About BioCurex, Inc:
BioCurex is a leading-edge biotechnology company with proprietary and patented technologies in the areas of cancer diagnosis and imaging. Testing results have consistently proven that BioCurex successfully detects over 90% of all breast cancers in tissue samples -- levels significantly above any present method. Ongoing studies are aimed at extending BioCurex' initial observations with other tumor tissues.
About P2000:
P2000 is a privately owned company, specialising in the sales, marketing and distribution of high value, third party products to the Portuguese hospital market. The company has firmly established itself as a leading player in the areas of biotechnology, hematology, immunology and transfusion medicine. Building on this success and with an eye to the future, P2000 is currently expanding into the high growth areas of cancer diagnostics, vaccines and surgical obesity. P2000 prides itself on its flexibility and the level of service provided to its partners and customers.
Note:
Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.